JPWO2020146529A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146529A5 JPWO2020146529A5 JP2021539637A JP2021539637A JPWO2020146529A5 JP WO2020146529 A5 JPWO2020146529 A5 JP WO2020146529A5 JP 2021539637 A JP2021539637 A JP 2021539637A JP 2021539637 A JP2021539637 A JP 2021539637A JP WO2020146529 A5 JPWO2020146529 A5 JP WO2020146529A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- compound
- pharmaceutical composition
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789937P | 2019-01-08 | 2019-01-08 | |
| US62/789,937 | 2019-01-08 | ||
| PCT/US2020/012783 WO2020146529A1 (en) | 2019-01-08 | 2020-01-08 | Methods of treating conditions related to the s1p1 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516662A JP2022516662A (ja) | 2022-03-01 |
| JPWO2020146529A5 true JPWO2020146529A5 (enExample) | 2023-01-20 |
Family
ID=69467760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539637A Ceased JP2022516662A (ja) | 2019-01-08 | 2020-01-08 | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220142977A1 (enExample) |
| EP (1) | EP3908276B1 (enExample) |
| JP (1) | JP2022516662A (enExample) |
| KR (1) | KR20210113298A (enExample) |
| CN (2) | CN118976023A (enExample) |
| AU (1) | AU2020206700A1 (enExample) |
| CA (1) | CA3124701A1 (enExample) |
| IL (1) | IL284114A (enExample) |
| MX (1) | MX2021008263A (enExample) |
| WO (1) | WO2020146529A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| DK3310760T3 (da) | 2015-06-22 | 2022-10-24 | Arena Pharm Inc | Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| WO2020072824A1 (en) * | 2018-10-03 | 2020-04-09 | Arena Pharmaceuticals, Inc. | Methods for the treatment of scleroderma |
| WO2025177319A2 (en) * | 2024-02-22 | 2025-08-28 | Msn Laboratories Private Limited, R&D Center | Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2326621T (pt) | 2008-07-23 | 2016-09-12 | Arena Pharm Inc | Derivados de ácido 1,2,3,4-tetrahidrociclopenta[b]indol-3-il) acético substituídos úteis no tratamento de distúrbios autoimunes e inflamatórios |
| PT2342205T (pt) * | 2008-08-27 | 2016-07-28 | Arena Pharm Inc | Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| US10040855B2 (en) * | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| PL3242666T3 (pl) * | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| JP6047203B2 (ja) * | 2015-02-20 | 2016-12-21 | セルセウティックス コーポレイション | 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬 |
-
2020
- 2020-01-08 CA CA3124701A patent/CA3124701A1/en active Pending
- 2020-01-08 EP EP20703633.6A patent/EP3908276B1/en active Active
- 2020-01-08 MX MX2021008263A patent/MX2021008263A/es unknown
- 2020-01-08 AU AU2020206700A patent/AU2020206700A1/en not_active Abandoned
- 2020-01-08 WO PCT/US2020/012783 patent/WO2020146529A1/en not_active Ceased
- 2020-01-08 JP JP2021539637A patent/JP2022516662A/ja not_active Ceased
- 2020-01-08 KR KR1020217024973A patent/KR20210113298A/ko active Pending
- 2020-01-08 US US17/421,299 patent/US20220142977A1/en not_active Abandoned
- 2020-01-08 CN CN202411067321.3A patent/CN118976023A/zh active Pending
- 2020-01-08 CN CN202080018255.4A patent/CN113874009A/zh active Pending
-
2021
- 2021-06-17 IL IL284114A patent/IL284114A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| US8003669B2 (en) | Remedy for sleep disturbance | |
| JP2505944B2 (ja) | （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| US7151093B2 (en) | Use of sphingosine 1-phosphate as active ingredient for the treatment of pulmonary fibrosis | |
| JP7025781B2 (ja) | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 | |
| TWI322689B (en) | Method for treating severe heart failure and medicament therefor | |
| TW201532606A (zh) | 使用化合物之組合治療ｃ型肝炎病毒感染 | |
| US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| CN1210465A (zh) | 治疗方法和药物组合物 | |
| TW200806630A (en) | Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as a medicament and medicament comprising them | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| JPWO2020146529A5 (enExample) | ||
| AU2008259864C1 (en) | Methods and compositions for administration of Oxybutynin | |
| EP4267127A1 (en) | Methods of treating cancer | |
| JP2002534379A5 (enExample) | ||
| US20130267593A1 (en) | Methods and compositions for administration of oxybutynin | |
| WO2006034631A1 (en) | Composition comprising amlodipine and angiotensin ii receptor blocker | |
| EP3119388A1 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
| TW201242597A (en) | A synergistic pharmaceutical combination for the treatment of pancreatic cancer | |
| JPWO2020112880A5 (enExample) | ||
| CN1305385A (zh) | 采用与白三烯抑制剂结合的特非那定代谢产物的方法和组合物 | |
| CN114853670B (zh) | 含有酰胺基团的喹啉类化合物及其制备与应用 | |
| TW200529847A (en) | Pharmaceutical composition for use in the treatment of chronic fatigue syndrome or fibromyalgia or associated functional symptoms of fibromyalgia | |
| JP2005511571A5 (enExample) | ||
| JPS60104019A (ja) | ウイルス感染症用薬剤 |